|
|
|
| Effect of Gefitinib on Tumor Markers of Stage IV Non-small Cell Lung Cancer Chemotherapy |
| PAN Xin-yan, LI Zhi-min |
| Dalian City Central Hospital, Liaoning Province 116033 |
|
|
|
|
Abstract Objective To investigate the effect of gefitinib in the treatment of stage IV non-small cell lung cancer (NSCLC). Methods A total of 72 patients with stage IV NSCLC in our hospital were divided into the observation group (n=34) and the control group (n=38). Patients in the control group were treated with cisplatin plus pimitrex, while patients in the observation group were given cisplatin plus gefitinib. The therapeutic effects and tumor marker changes in the two groups were compared. Results The short-term curative effect of the observation group was significantly better than that of the control group (P<0.05), which of clinical effective rates were 91.18% and 81.58%, respectively; The rates of bone marrow suppression and diarrhea in the observation group were significantly higher than those in the control group (P<0.05);After treatment, the paracancerous antigen (CEA), cytokeratin fragment 21-1 (CYFRA21-1) and squamous cell carcinoma antigen (SCCA) in the observation group were (30.03±11.02) g/L, (25.58±6.22)g/L and (25.50±5.44) g/L,respectively, which were significantly lower than those of the control group (P<0.05).The median progression-free survival time and overall survival in the observation group were 9 months and 13 months, respectively, which were significantly longer than those in the control group (5 months and 9 months, respectively) (P<0.05). Conclusion Gefitinib has good clinical efficacy in the treatment of stage Ⅳ non-small cell lung cancer patients, which can significantly reduce CEA, CYFRA21-1 and SCCA levels. It is worthy of clinical use.
|
|
Received: 17 July 2018
|
|
|
|
|
|
[1] 徐燕, 王孟昭. 非小细胞肺癌免疫治疗进展[J].国际呼吸杂志, 2016, 36(18):277-281.
[2] 王巍, 刘冉生, 张爱旭,等. 不同放疗时机对诱导化疗的局限型NSCLC患者疗效、免疫功能及预后的影响[J].山东医药, 2016, 56(17):19-21.
[3] 魏智民, 张维强, 高峰,等. 淋巴细胞亚群对晚期非小细胞肺癌患者化疗效果及远期生存的影响[J].中国医学科学院学报, 2017, 39(3):371-376.
[4] Lally BE, Zelterman D, Colasanto JM,et al.Postoperative radiotherapy for stage Ⅱ or Ⅲ non-small-cell lung cancer using the surveillance, epidemiology, and end results database[J].J Clin Onc,2016, 24(19):2998-3006.
[5] 彭东旭, 方晓娟, 杜均详,等. 培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响[J].临床肺科杂志, 2016, 21(7):1306-1309.
[6] 郭刚, 李恒, 郭琦,等. 吉非替尼对非小细胞肺癌患者免疫功能的影响[J].中国临床药理学杂志, 2016, 32(6):505-507.
[7] 朱辉, 李智勇. PET/CT联合CEA、CA125、CYFRA21-1检测在鉴别诊断晚期肺癌的应用研究[J].广西医科大学学报, 2016, 33(3):495-497.
[8] Wang PY, Department O.Study on the Short-term Efficacy and Side Effects of Pemetrexed in the Treatment of Recurrent Advanced Non-small Cell Lung Cancer[J].China & Foreign Medical Treatment,2015. |
|
|
|
2019, Vol. 36 
